Clinical Trials Logo

HR-positive Breast Cancer clinical trials

View clinical trials related to HR-positive Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05508906 Recruiting - Clinical trials for Metastatic Breast Cancer

Phase 1b Combo w/ Ribociclib and Alpelisib

Start date: August 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).

NCT ID: NCT04448886 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Start date: September 23, 2020
Phase: Phase 2
Study type: Interventional

This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: - Sacituzumab govitecan (IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)

NCT ID: NCT04205786 Suspended - Clinical trials for HR-positive Breast Cancer

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

Start date: August 12, 2021
Phase: N/A
Study type: Interventional

Treatment of hormone receptor (HR)-positive breast cancer with Aromatase Inhibitors (AIs) can lead to associated musculoskeletal pain and may cause patients to discontinue important treatment. This is a randomized controlled trial assessing the affect of Vitamin B12 on AI-associated joint pain and other outcomes. Participants will be randomly assigned 1:1 to treatment or control arm. The primary objective of this study is: -To assess whether daily oral Vitamin B12 decreases average joint pain in women with AI-Associated Musculoskeletal Symptoms Secondary objectives include: - To investigate whether daily vitamin B12 improves functional quality of life - To explore the impact of treatment on serum inflammatory cytokine levels (C- reactive protein) between baseline and various points in treatment.